AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|
22.3 C
New York
Tuesday, September 1, 2026

Tag: women

Xinhua Silk Road: Thematic cultural week held in SE China county to deepen cross-Strait exchanges

BEIJING, June 14, 2026 /PRNewswire/ -- From June 10 to June 12, Chen Jinggu Cultural Activities Week, a sub-event of the 18th Straits Forum, drew...

WANDA Week Celebrates 10 Years of Food Sheroes during Juneteenth

WASHINGTON, June 14, 2026 /PRNewswire/ -- Women Advancing Nutrition, Dietetics, and Agriculture (WANDA) marks its 10th anniversary with WANDA Week, June 14–20, 2026, a...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

MUSSO E80 Muse Ergonomic chair for petite women releasing in USA

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement

Discover ingredients, urinary microbiome science, benefits, and why thousands of women are discussing FemiCore in 2026.
Discover ingredients, urinary microbiome science, benefits, and why thousands of women are discussing FemiCore in 2026.

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

FemiCore bladder control capsules 2026 — ingredient information, probiotic strain details, official website verification guidance, and the counterfeit-marketplace red flags consumers are encouraged to be aware of in the women's health supplement category.
FemiCore bladder control capsules 2026 — ingredient information, probiotic strain details, official website verification guidance, and the counterfeit-marketplace red flags consumers are encouraged to be aware of in the women's health supplement category.

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Wells Fargo Foundation Provides $1 Million Grant to Expand Capital Access for Broward County Entrepreneurs

Ascendus to deploy $900,000 in loans and pair every dollar with hands-on coaching, from Prospera and other partners, supporting an estimated 160 local jobs...

Bishop’s University Will Host a New Research Chair in Quebec English Studies

SHERBROOKE, QC, June 12, 2026 /CNW/ - For more than fifty years, the English-speaking communities of Quebec have navigated profound change, their history underexplored and their...

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsWomen